Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

What Does the Published Research Say About FOXO4-DRI?

Research Context

  • The packet contains one human-context study in oncology (senescence-targeting in NSCLC radiotherapy) and multiple reviews/mechanistic papers plus several preclinical studies on FOXO4-DRI or related FOXO4 peptides.
  • Reviews and mechanistic work on cellular senescence and the FOXO4–p53 interaction provide rationale, but they do not substitute for primary human outcome evidence [pubmed:40593617; pubmed:29260442; pubmed:29471104; pubmed:29171222; pubmed:42024235].
  • Claims below are limited to what the supplied citations support and are separated by evidence tier.

Key Takeaway

No human trials of FOXO4-DRI are included. One NSCLC radiotherapy study targeted senescence-like fibroblasts (not FOXO4-DRI). Evidence specific to FOXO4-DRI is preclinical or mechanistic.

Direct Answer

  • Human evidence in this packet pertains to an NSCLC radiotherapy context that targeted senescence-like fibroblasts; FOXO4-DRI was not tested [pubmed:34877934]. Any radiosensitization and reduced radiation-induced pulmonary fibrosis findings are part of that translational program and should not be assumed to be human-only outcomes.
  • For FOXO4-DRI specifically, the packet provides mechanistic and preclinical (animal/in vitro) studies indicating senolytic activity via the FOXO4–p53 axis. These do not establish human efficacy, safety, dosing, delivery, or generalized anti-aging effects.

Human Evidence (specific to the cited population and endpoints)

  • NSCLC radiotherapy context [pubmed:34877934]
  • Study focus: targeting senescence-like fibroblasts during radiotherapy for non-small cell lung cancer.
  • As reflected in the publication title, the translational program links this approach with tumor radiosensitization and reduced radiation-induced pulmonary fibrosis across its experimental tiers.
  • FOXO4-DRI was not used; conclusions should remain confined to this NSCLC radiotherapy context.

Review and Mechanistic Context (not human outcome evidence)

  • Mechanistic interface of FOXO4 with p53:
  • The disordered p53 transactivation domain is identified as a target of FOXO4 and of FOXO4-DRI, clarifying a proposed senolytic mechanism; this is not clinical efficacy evidence [pubmed:40593617].
  • Broader senescence and translational framing:
  • Cellular senescence in kidney aging and transplantation [pubmed:29260442; pubmed:29471104].
  • Broader aging and interventional concepts [pubmed:29171222].
  • Conceptual review on retro-inverso peptides targeting the FOXO4–p53 axis in brain aging and cognition [pubmed:42024235].

Preclinical Evidence (animal/in vitro; model-specific and not established in humans)

Note: In vitro findings using human-derived cells are preclinical and do not constitute clinical evidence.

Dermal/keloid

  • FOXO4-DRI induced apoptosis in senescent human keloid fibroblasts in vitro, associated with p53 Ser15 phosphorylation changes and nuclear exclusion [pubmed:39994346].

Reproductive/Leydig–testis

  • FOXO4-DRI reduced SASP secretion from Leydig cells and improved spermatogenesis in aged mice (in vivo) [pubmed:39025385].
  • FOXO4-DRI alleviated age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice (in vivo) [pubmed:31959736].

Pulmonary fibrosis

  • A non-DRI FOXO4 peptide (peptide identity not specified as DRI) ameliorated bleomycin-induced pulmonary fibrosis in mice; pathway analysis implicated ECM–receptor interactions (in vivo) [pubmed:35510614].

Vascular/endothelium

  • FOXO4-DRI regulated endothelial cell senescence via p53 signaling in preclinical endothelial models (model systems; non-clinical) [pubmed:41625068].

Cartilage/chondrocytes

  • FOXO4-DRI selectively removed senescent cells from in vitro expanded human chondrocytes (in vitro) [crossref:10.3389/fbioe.2021.677576].

Liver (combination context)

  • Morphological liver changes were reported in experimental animals receiving combined adribastin and FOXO4-DRI (in vivo; descriptive histology). This is not a human safety profile [crossref:10.34680/2076-8052.2023.2(131).216-222].

Comparative senolytic (context only; not FOXO4-DRI evidence)

  • Ionophore nigericin explored as an alternative senolytic strategy in preclinical models [pubmed:36430735].

Notes on model scope

  • Several preclinical studies involve FOXO4-DRI specifically (keloid fibroblasts, Leydig/testis, endothelial models, human chondrocytes), while others use a generic/non-DRI FOXO4 peptide (e.g., pulmonary fibrosis). Findings with non-DRI FOXO4 peptides should not be conflated with FOXO4-DRI.

What Is Not Established by This Packet

  • No direct clinical efficacy or safety data for FOXO4-DRI in humans are provided.
  • Preclinical (animal/in vitro) results should not be treated as established human outcomes.
  • Dosing, delivery method, tolerability, adverse events, and long-term effects in humans are not addressed by the supplied citations.
  • The NSCLC radiotherapy study did not test FOXO4-DRI; its endpoints belong to a broader translational program.
  • Patent listings are included for completeness and are not used as efficacy or safety evidence.

FAQ

  • Has FOXO4-DRI been tested in humans in this packet?
  • No. The packet provides no human trials of FOXO4-DRI. The one human-context study in NSCLC radiotherapy did not use FOXO4-DRI [pubmed:34877934].
  • What mechanism is proposed for FOXO4-DRI?
  • Mechanistic research identifies the disordered p53 transactivation domain as a target of FOXO4 and FOXO4-DRI, supporting a senolytic hypothesis [pubmed:40593617]. This is not clinical efficacy evidence.
  • Do in vitro results in human cells (e.g., chondrocytes or keloid fibroblasts) count as clinical evidence?
  • No. These are preclinical studies and do not establish outcomes in people [crossref:10.3389/fbioe.2021.677576; pubmed:39994346].
  • Are FOXO4 peptide studies interchangeable with FOXO4-DRI findings?
  • Not necessarily. Some studies use a generic/non-DRI FOXO4 peptide; those results should not be conflated with FOXO4-DRI [pubmed:35510614].
  • Does the packet address dosing, delivery, or tolerability for FOXO4-DRI in humans?
  • No. These aspects are unaddressed in the supplied literature.

References

Human/clinical-context

  • [pubmed:34877934]

Review/mechanistic context

  • [pubmed:40593617]; [pubmed:29260442]; [pubmed:29471104]; [pubmed:29171222]; [pubmed:42024235]

Preclinical (animal/in vitro)

  • [pubmed:39994346]; [pubmed:39025385]; [pubmed:31959736]; [pubmed:35510614]; [pubmed:41625068]; [crossref:10.3389/fbioe.2021.677576]; [crossref:10.34680/2076-8052.2023.2(131).216-222]; [pubmed:36430735]

Other sources in packet (not used as efficacy or safety evidence)

  • [patent_search:foxo4-dri-foxo4-dri-peptide-senescence]

Related FOXO4-DRI resources

Use the pages below to separate technical identity, gated catalog access, and anecdotal discussion from the evidence review on this page.